Showing all 3 results
Apixaban Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, High-Bioavailability Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the active API.
Active Ingredient Strength Primary Clinical Function Apixaban USP/Ph.Eur. 2.5 mg The Dose-Reduction Unit: Used for patients with specific risk factors (Age ≥80, Weight ≤60kg, or high Creatinine) to minimize bleeding. Apixaban USP/Ph.Eur. 5 mg The Therapeutic Anchor: The standard maintenance dose for stroke prevention in Atrial Fibrillation and DVT treatment. Excipients Proprietary Matrix Rapid-Dissolution System: Engineered to ensure a consistent $T_{max}$ of approx. 3 to 4 hours for reliable protection. Rivaroxaban Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Engineered Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the potent DOAC molecule.
Active Ingredient Strength Primary Clinical Function Rivaroxaban INN/Ph.Eur. 2.5 mg Vascular Dose: Co-administered with Aspirin to prevent major cardiovascular events in CAD/PAD. Rivaroxaban INN/Ph.Eur. 10 mg Surgical Prophylaxis: Prevention of DVT following knee or hip replacement surgery. Rivaroxaban INN/Ph.Eur. 15 mg / 20 mg Global Clinical Standard: Treatment of acute DVT/PE and stroke prevention in Atrial Fibrillation. Excipients Microcrystalline Cellulose / Croscarmellose Sodium / Hypromellose / Sodium Lauryl Sulfate / Magnesium Stearate Diluent / Superdisintegrant / Surfactant (Engineered for optimal solubilization and synchronized gastrointestinal absorption) *Pack Sizes: 10×10 Alu-Alu Blisters or 14/28/30-Tablet Blisters (Optimized specifically for strict chronic cardiology and acute post-op dispensing regimens).
Ticagrelor Tablets
FreeTicagrelor tablets primarily contain Ticagrelor as the active pharmaceutical ingredient. It is a direct-acting P2Y12 receptor antagonist used as an antiplatelet medication to prevent blood clots in patients with a history of heart attack or acute coronary syndrome (ACS)
